GTC Biotherapeutics (fka GTCB)

[keitern]

Jesse, we agree on GTC being undervalued and under appreciated. For example GTC has an almost assured eventual 25+mil gross profit in Atryn HD ramping over the next 3 years. That kind of high margin revenue should receive a multiple from interested companies. Undoubtedly the delay in partnership is related to a gap between what GTC knows that revenue stream is worth (not to mention prospects in other Atryn INDs) and what has been offered so far. The science is validated, low hanging fruit is getting ripe, and patience is required. I hope GTC doesn't rush into any deal that doesn't fairly value its assets. They just need to keep negotiating.

PS: I thought you had a collection of guitars. I guess it was someone else.